Polyrizon Ltd. (PLRZ) Enterprise Value to EBITDA Ratio

Polyrizon Ltd (PLRZ) is exposed to risks stemming from raw material logistics disruptions and export barriers, which complicate patent protection. The stock's price history visualizes the development of the Capture and Confine nasal barrier system, which creates a protective layer against allergens, while the EV/EBITDA ratio stands at 0.00. Business stability is ensured by a lean staff of biopolymer experts, eliminating the loss of key scientific knowledge.

Polyrizon - PLRZ Company Value to EBITDA (period 11/23/2025 - 11/10/2026)

Comprehensive metric breakdowns and analytics for polyrizon-biotech.com (PLRZ)

- current price and projected stock value:

Stock Price Polyrizon|PLRZ - Analyst Median Target

- market capitalization details:

Market Valuation Polyrizon|PLRZ - Full Business Value

- business book valuation details:

Book Value per Share Polyrizon|PLRZ - Total Stockholders' Equity|Market Capitalization to Book Value Ratio polyrizon-biotech.com|PLRZ - Total Business Assets

- debt burden and liquidity indicators:

- financial results and valuation multiples details:

PLRZ - Final Profit|Expected Profit Polyrizon Ltd|PLRZ - Price to Earnings Ratio|Forward P/E Multiple Polyrizon|PLRZ - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Polyrizon|PLRZ - Profit before deduction of interest, taxes, depreciation and amortization|Earnings per share for the last twelve months Polyrizon|PLRZ - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months polyrizon-biotech.com|PLRZ - Earnings per share growth in current year|Expected earnings per share growth for next year Polyrizon Ltd

Fundamental valuation:Polyrizon Ltd. PLRZ

This ratio determines the total enterprise value relative to its operating profit before depreciation, taxes, and interest. By analyzing the EV/EBITDA multiple over time, an investor assesses the company's resilience to debt loads and inflationary pressure on costs. For Polyrizon Ltd (PLRZ), this indicator is critically important as it reflects the capitalization efficiency of development costs for innovative barrier sprays.

Key competitors

EV/EBITDA Multiple VRTX (Vertex Pharmaceuticals Inc.)|Total Company Value to Operating Income Before Depreciation Ratio Alnylam Corp (ALNY)|INSM: Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio UTHR|BMRN: EV/EBITDA Multiple|Company Value to EBITDA BridgeBio Pharma (BBIO)|BGM (BGM Group Limited) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation COGT (Cogent Corp)|Enterprise Value to EBITDA Ratio XERS (Xeris Biopharma)|KROS (kerostx.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Arcturus Therapeutics Holdings Inc. ARCT|ETON (Eton Pharmaceuticals Inc) - Company Value to Operating Income Before Depreciation Ratio|Kamada Corp - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation FULC (Fulcrum Corp)|ABEO: EV/EBITDA Multiple|Mereo BioPharma Group plc (MREO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protalix BioTherapeutics, Inc.|PLRX: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Applied Therapeutics (APLT)|Enterprise Value to EBITDA Ratio Aileron Therapeutics RNTX|EV/EBITDA Multiple GELS (Gelteq)|EV/EBITDA Multiple Aytu BioPharma Inc AYTU|CMMB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio SRXH|zentaris.com (AEZS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Cyclo Therapeutics, Inc (CYTH)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Inozyme Pharma Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization RPHM|Enterprise Value to EBITDA Ratio CSCI (COSCIENS Biopharma)